ABY-029 can be used in intraoperative fluorescent-guided surgery of glioma in order to improve detection of the tumor-to-normal tissue boundary and decrease the residual tumor cells surrounding the tumor margin, which is the key to improved prognosis of following resection of glioblastoma. The value of increasing the injected dose above a microdose appears clear, providing significant 2-fold increase in contrast and also a longer term increase extending out to 24 h. However, it is possible to see contrast in glioma tumors with injected doses as low as a standard FDA microdose level. GMP production of ABY-029 is in progress, and toxicological studies have been completed to confirm the safety of the molecular-targeted fluorescent probe for future clinical trial .